Abstract
Elevated D-dimer and other markers of coagulation disturbances are predictors of severity and mortality in COVID-19 patients and heparin use during hospital stay has been associated to a decreased mortality. Similar findings have been described in other coronaviruses. COVID-19 patient autopsies have revealed thrombi in the microvasculature, suggesting intravascular coagulation as a prominent feature of organ failure and of the acro-ischaemia increasingly reported in these patients. In COVID-19 pulmonary compliance is preserved despite severe hypoxemia, contrarily to classic ARDS, corroborating the hypothesis that perfusion mismatch may play a significant role in the development of respiratory failure in these patients. Based on this rationale, a series of 27 consecutive COVID-19 patients admitted to our hospital were treated with heparin in doses tailored to clinical severity, ranging from 1 - 2 mg/kg of enoxaparin BD. PaO2/FiO2 ratio increased significantly over the 72 hours following the start of anticoagulation, from 254(SD 90) to 325(SD 80), p=0.013, and over half of the patients were discharged home within an average time of 7.3 (SD 4.0) days. Half of mechanically ventilated patients were extubated within 10.3 (SD 1.5) days. The remaining patients showed progressive, albeit slower improvement, and both the mortality and the bleeding complications rate in these patients were absent.
Even though this uncontrolled case series does not offer absolute proof of DIC as the underlying mechanism of respiratory failure in COVID-19, as well as patients positive response to tailored dose heparinization, it contributes to the understanding of the physiopathological mechanism of the disease and provides valuable information for the treatment of these very sick patients while we await the results of further prospective controlled studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This was a retrospective study based on medical records data with no funding needed.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be provided if requested. It contais confidential medical records.
